Press "Enter" to skip to content

German Company CureVac Vaccine Final Trail Shows 48% Efficacy

German Company CureVac announced on Wednesday the final results of its late-stage vaccine trial, confirming earlier data showing that its shot is far less protective than other vaccines. The vaccine had an efficacy of just 48% against Covid-19.

The Moderna and Pfizer-BioNTech vaccines, which use the same mRNA technology as CureVac’s, delivered efficacy rates of around 95% in clinical trials.CureVac’s vaccine proved somewhat better for younger volunteers like those between the ages of 18 and 60, the efficacy rose to 53%. In that group, the researchers also found the vaccine provided 100% protection against hospitalization and death.

Forty thousand people participated in the company’s trial in Europe and Latin America. By the end of the study, 288 volunteers had gotten Covid-19.German Company CureVac had to contend with 15 different variants of the coronavirus. Genetic testing showed that only 3% of the cases were caused by the original version of the coronavirus. It’s possible that some of the variants were able to escape the immunity stimulated by the vaccine.

The vaccine experts have also questioned whether part of CureVac’s problem was with the design of the vaccine itself. The precise recipe that German Company CureVac used to build its vaccine may have blunted its effectiveness. Weissman’s research has shown that using messenger RNA without modifications can interfere with T cells involved in developing a robust immune response.The European Medicines Agency opened a rolling review of CureVac’s vaccine in February, and the company said it would continue its submission with this data. The vaccine will be an important contribution to help manage the Covid-19 pandemic and the dynamic variant spread.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *